Institut de Canc rologie de la Loire(0.0 mi away)Contact
+17 other location
kidney function tests
soft tissue sarcoma
Phase III, multicenter, randomized open-label and comparative study designed to demonstrate
whether adding 4 cycles of peri-operative doxorubicin-based chemotherapy improves
metastasis-free survival as compared with standard management in patients with resectable
FNCLCC grade 1/2 STS, considered as high-risk according to CINSARC (Complexity Index in
After signed informed consent, patients considered as eligible to CHIC-STS study by the
investigator will be enrolled in the study and a molecular screening will be performed (600
patients will be screened).
Patients considered as low-risk according to CINSARC signature will be treated at the
discretion of the clinicians (prospective cohort).
Patients considered as high-risk according to CINSARC signature will be randomized in the
open-label multicenter phase III trial and assigned in one of the two following treatments
Arm A (control arm): Standard of care (surgical excision +/- external radiotherapy).
Arm B (experimental arm): Standard of care + 4 cycles of intravenous chemotherapy during
A total of 250 patients will have to be randomized with 125 patients in each arm.
Standard of Care,
Standard of care + chemotherapy
Clinical Study Identifier
Institut Claudius Regaud
Last Modified on
11 November 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.